~~<i id='C9FAA2B111'><strike id='C9FAA2B111'><tt id='C9FAA2B111'><pre id='C9FAA2B111'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：knowledge 2025-09-14 10:05:50 - browse：168

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Keeping primary care docs in field isn't impossible, says AAFP CEO

leisure time

focus

entertainment

explore

leisure time

AdobeHealthprofessorNeilWengerwasdeepintoayears-longstudyonseriouslyillprimarycarepatientswhenheunco

WSS

Carvykti CAR

ALS treatment from Biogen, Ionis fails in study

Fertility clinic egg and embryo storage is a disaster

Violet CEO on training clinicians to promote more inclusive care

SNAP should offer more nutrition education

Readout Newsletter: The latest on Moderna, Apellis, and Merck

focus

entertainment

leisure time

Walensky prepares to leave CDC — and Congress — behind

Galapagos to make CAR

Affirmative action in medical school literally saved lives

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Walensky prepares to leave CDC — and Congress — behind

Why health care costs have stayed mostly flat since 2010

Anesthesiologist group: stop taking Ozempic before surgery

WuXi Biologics execs register to lobby as Congress comes for the company

Moonlake's readout produced a cash windfall. Risks remain

Keeping primary care docs in field isn't impossible, says AAFP CEO

focus

Grail spinoff by Illumina should end disastrous merger attempt

Oak Street deal isn't the answer to health care's woes

Galapagos to make CAR

HHS suspends federal funding for EcoHealth Alliance

Three trends to watch in biotech in 2024

ALS treatment from Biogen, Ionis fails in study

entertainment

explore

explore

leisure time